CATO 佳途CATO · CNAS + ANAB ISO 17034 双体系认可标准物质生产者CNAS + ANAB ISO 17034 dual-accredited reference material producer
销售顾问Sales contact 卢振明Kaka Lu+86 185 2048 1969kaka@cato-chem.com
Miglitol

米格列醇 杂质对照品Miglitol Impurities

19 个杂质条目19 impurity entries

本页汇总 米格列醇 的 19 个杂质对照品条目。杂质谱是仿制药杂质研究、方法开发与稳定性考察的起点——先锁定品种,再逐条比对结构差异与保留行为。This page collects 19 impurity reference standards of Miglitol. The impurity profile is the starting point for related-substance method development, forced degradation and stability studies.

批量索取报价 / COABulk quote / COA在全站目录中检索Search the full catalogue

相关研究文献Related literature

以下为 米格列醇(Miglitol)在公开文献中的研究报道(题录信息,来源 PubMed),供方法开发与文献调研参考。Selected peer-reviewed publications on this drug substance — bibliographic records from PubMed.

  1. 杂质研究Impurity studiesDevelopment and Validation of Miglitol and Its Impurities by RP-HPLC and Characterization Using Mass Spectrometry Techniques
    Scientia pharmaceutica · 2016 · Balakumaran K et al.  ·  PMID 27754407  ·  DOI
  2. 杂质研究Impurity studiesA sensitive and selective method for the quantitative analysis of miglitol in rat plasma using unique solid-phase extraction coupled with liquid chromatography-tandem mass spectrometry
    Biomedical chromatography : BMC · 2014 · Mizuno-Yasuhira A et al.  ·  PMID 24706526  ·  DOI
  3. 分析方法Analytical MethodsStability-Indicating RP-HPLC Method for Estimation of Miglitol in Bulk and Tablets
    Indian journal of pharmaceutical sciences · 2010 · Shrivastava B et al.  ·  PMID 21969753  ·  DOI
  4. 分析方法Analytical MethodsKinetic determination of acarbose and miglitol in bulk and pharmaceutical formulations using alkaline potassium permanganate
    International journal of biomedical science : IJBS · 2007 · Ibrahim FA et al.  ·  PMID 23675017
  5. 分析方法Analytical MethodsDetermination of Miglitol by Column-Switching Ion-Pair HPLC with Tris(2,2'-bipyridine)ruthenium(II)-Electrogenerated Chemiluminescence Detection
    Chemical & pharmaceutical bulletin · 2015 · Asamoto H et al.  ·  PMID 26027473  ·  DOI

米格列醇 —— 原料药与杂质对照品Miglitol — drug substance & impurities

共 20 个条目(含原料药本体)20 items incl. the drug substance
Miglitol structure
原料药 APIAPI
米格列醇Miglitol
Miglitol
CAS No.72432-03-2
Chemical FormulaC8H17NO5
Purity>95%询价On request
10mg25mg50mg100mg
Miglitol Impurity 2 structure
2
米格列醇杂质2Miglitol Impurity 2
Miglitol Impurity 2
CAS No.132310-34-0
Chemical FormulaC8H17NO5
Purity>95%询价On request
10mg25mg50mg100mg
Miglitol impurity N2 structure
N2
米格列醇杂质N2Miglitol impurity N2
Miglitol impurity N2
CAS No.2230722-74-2
Chemical FormulaC8H17NO6
Purity>95%现货In stock
10mg25mg50mg100mg
Miglitol Impurity 3(Deoxynojirimycin) structure
3
米格列醇杂质3(脱氧野尻霉素)Miglitol Impurity 3(Deoxynojirimycin)
Miglitol Impurity 3(Deoxynojirimycin)
CAS No.19130-96-2
Chemical FormulaC6H13NO4
Purity>95%询价On request
10mg25mg50mg100mg
3
米格列醇杂质3Miglitol Impurity 3
Miglitol Impurity 3
CAS No.2230715-33-8
Chemical FormulaC10H21NO6
Purity>95%现货In stock
10mg25mg50mg100mg
Miglitol Impurity 4 structure
4
米格列醇杂质4Miglitol Impurity 4
Miglitol Impurity 4
CAS No.1370331-33-1
Chemical FormulaC8H17NO5
Purity>95%询价On request
10mg25mg50mg100mg
Miglitol Impurity 5 structure
5
米格列醇杂质5Miglitol Impurity 5
Miglitol Impurity 5
CAS No.52541-36-3
Chemical FormulaC7H9NO2
Purity>95%询价On request
10mg25mg50mg100mg
Miglitol Impurity 6 structure
6
米格列醇杂质6Miglitol Impurity 6
Miglitol Impurity 6
CAS No.1824614-40-5
Chemical FormulaC8H11NO2
Purity>95%询价On request
10mg25mg50mg100mg
Miglitol Impurity 7 structure
7
米格列醇杂质7Miglitol Impurity 7
Miglitol Impurity 7
CAS No.1550201-56-3
Chemical FormulaC8H17NO5
Purity>95%询价On request
10mg25mg50mg100mg
Miglitol Impurity 8 structure
8
米格列醇杂质8Miglitol Impurity 8
Miglitol Impurity 8
CAS No.142345-67-3
Chemical FormulaC8H17NO6
Purity>95%询价On request
10mg25mg50mg100mg
Miglitol Impurity 9 structure
9
米格列醇杂质9Miglitol Impurity 9
Miglitol Impurity 9
CAS No.54662-27-0
Chemical FormulaC8H19NO6
Purity>95%询价On request
10mg25mg50mg100mg
Miglitol Impurity 10 structure
10
米格列醇杂质10Miglitol Impurity 10
Miglitol Impurity 10
CAS No.164024-55-9
Chemical FormulaC16H22O6
Purity>95%询价On request
10mg25mg50mg100mg
Miglitol Impurity 11 structure
11
米格列醇杂质11Miglitol Impurity 11
Miglitol Impurity 11
CAS No.1824645-71-7
Chemical FormulaC8H11NO3
Purity>95%询价On request
10mg25mg50mg100mg
Miglitol Impurity 12 structure
12
米格列醇杂质12Miglitol Impurity 12
Miglitol Impurity 12
CAS No.1246812-05-4
Chemical FormulaC8H17NO5
Purity>95%询价On request
10mg25mg50mg100mg
Miglitol Impurity 12 Hydrochloride structure
12
米格列醇杂质12 盐酸盐Miglitol Impurity 12 Hydrochloride
Miglitol Impurity 12 Hydrochloride
CAS No.1322625-07-9
Chemical FormulaC8H17NO5·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Miglitol Impurity 15 structure
15
米格列醇杂质15Miglitol Impurity 15
Miglitol Impurity 15
CAS No.69567-10-8
Chemical FormulaC7H15NO4
Purity>95%询价On request
10mg25mg50mg100mg
Miglitol Impurity 17 structure
17
米格列醇杂质17Miglitol Impurity 17
Miglitol Impurity 17
CAS No.2512224-22-3
Chemical FormulaC8H17NO5·HCl
Purity>95%询价On request
10mg25mg50mg100mg
Miglitol Impurity 20 (N-Nitroso Miglitol Impurity 3) structure
20
米格列醇杂质20 (N-亚硝基米格列醇杂质3)Miglitol Impurity 20 (N-Nitroso Miglitol Impurity 3)
Miglitol Impurity 20 (N-Nitroso Miglitol Impurity 3)
CAS No.1932484-87-1
Chemical FormulaC6H12N2O5
Purity>95%询价On request
10mg25mg50mg100mg
Miglitol Impurity 21 structure
21
米格列醇杂质21Miglitol Impurity 21
Miglitol Impurity 21
CAS No.936567-41-8
Chemical FormulaC10H21NO3
Purity>95%询价On request
10mg25mg50mg100mg
Miglitol Impurity 30 structure
30
米格列醇杂质30Miglitol Impurity 30
Miglitol Impurity 30
CAS No.3113389-97-9
Chemical FormulaC43H47NO5
Purity>95%询价On request
10mg25mg50mg100mg
本品种含亚硝胺类杂质条目。亚硝胺杂质属于 ICH M7 关注的潜在致突变杂质,建议在方法开发中纳入专属性考察。This list includes nitrosamine entries. Nitrosamines are potential mutagenic impurities under ICH M7 and should be covered by a specific method.

结构式清晰度以随货 COA 与厂家图谱为准;目录之外的杂质可按需定制合成或调取。Structural confirmation is governed by the COA and manufacturer spectra. Impurities outside this list can be custom-synthesised or sourced on request.

Literature & synthesis

米格列醇 —— 研究文献与合成路线Miglitol — literature & synthetic routes

以下题录由公开学术数据库按品种名检索汇总,供 米格列醇 的杂质谱研究、分析方法开发与工艺路线选择参考。文献题名与专利标题均可点击查看原文,版权归原作者与出版方所有。Citations below are aggregated from public scholarly databases by drug-substance name, for reference in impurity profiling, analytical method development and route selection for Miglitol. Titles link to the original records; copyright remains with the authors and publishers.

杂质与降解研究文献Impurity & degradation studies

  1. Development and Validation of Miglitol and Its Impurities by RP-HPLC and Characterization Using Mass Spectrometry Techniques
    Balakumaran K, Janagili M, Rajana N, et al. · Scientia pharmaceutica · 2016 · 被引 2cited 2
  2. Kinetic determination of acarbose and miglitol in bulk and pharmaceutical formulations using alkaline potassium permanganate
    Ibrahim FA, Ali FA, Ahmed SM, et al. · International journal of biomedical science : IJBS · 2007 · 被引 3cited 3

合成与制备工艺专利Synthesis & process patents

  1. Process for producing miglitol key intermediate
    ZHIQUAN ZHAO · 公开号 CN101492380CN101492380 · 2009
  2. Preparation of miglitol
    SU GUOQIANG, CAI YUZHU · 公开号 CN1680321CN1680321 · 2005
  3. High-purity miglitol production process
    MIAO ZHOU, XINQIANG SUN, SANMING HU · 公开号 CN101302549CN101302549 · 2008
  4. Miglitol crystal and method for preparing same
    SANMING HU, ZHENGLI TAO, XINQIANG SUN · 公开号 CN101289418CN101289418 · 2008
  5. Industrial miglitol producing process
    ZHAO ZHIQUAN PENG · 公开号 CN1740166CN1740166 · 2006

题录与链接来自公开数据库 Europe PMC(含 PubMed 与全球专利题录)与 WIPO PatentScope,本站仅提供索引,不转载正文;如链接失效请以数据库检索为准。Citations are indexed from public databases (Europe PMC incl. PubMed and patent records, WIPO PatentScope); we provide links only and do not reproduce full text.

For formulation & analytical R&D

米格列醇 杂质谱研究要点Miglitol — impurity profiling notes

下面这些是拿到 米格列醇 的 20 个杂质条目之后,仿制药研发最常遇到的几件事。先把杂质的来源分清,再决定要不要买对照品、买哪几个。Once you have the 20 impurity entries for Miglitol, these are the questions that come up most in generic development. Classify the source of each impurity first, then decide which reference standards you actually need.

01工艺杂质Process impurities

起始物料、中间体、副产物、催化剂与溶剂残留。多来自合成路线本身,应在工艺开发阶段用加标试验定位。Starting materials, intermediates, by-products, catalysts and residual solvents — traced back to the synthetic route and located with spiking studies during process development.

02降解杂质Degradation impurities

水解、氧化、光解、高温高湿与聚合产物。需通过强制降解试验识别,并确认方法具备稳定性指示能力。Hydrolytic, oxidative, photolytic, thermal and polymeric degradants — identified through forced degradation, with the method proven stability-indicating.

03药典杂质Pharmacopoeial impurities

EP/USP 已收载并有官方编号的杂质(如 EP Impurity A、USP Related Compound B)。申报时通常需逐项对照。Impurities already monographed with official designations (e.g. EP Impurity A, USP Related Compound B), normally compared item by item during filing.

04基因毒性杂质Genotoxic impurities

含警示结构、需按 ICH M7 进行危害评估与限度推导(TTC 1.5 µg/日)。该类杂质必须用对照品准确控制。Structurally alerting compounds requiring ICH M7 hazard assessment and limit derivation (TTC 1.5 µg/day); these must be controlled with an authentic reference standard.

05同位素标记物Isotopically labelled standards

氘代、¹³C、¹⁵N 标记的同类物,主要用作 LC-MS/MS 生物分析的内标,抵消基质效应与回收率波动。Deuterated, ¹³C- and ¹⁵N-labelled analogues used as internal standards in LC-MS/MS bioanalysis to compensate matrix effects and recovery variation.

06代谢与转化产物Metabolites & conversion products

体内代谢物、强制降解转化物与工艺中间态,常见于杂质谱比对与稳定性考察中。In-vivo metabolites, forced-degradation products and process intermediates encountered in impurity profiling and stability studies.

方法开发与对照品使用建议Method development and standards usage

先定分离,再谈定量Resolution first, then quantification

主成分与相邻杂质峰分离度应 ≥1.5;用杂质对照品确定相对保留时间与相对响应因子,避免用自身对照法掩盖响应差异。Target baseline resolution ≥1.5 between the main component and adjacent impurities; establish relative retention and relative response factors with authentic impurity standards rather than relying on self-comparison.

校正因子不可忽略Never ignore response factors

紫外吸收差异大的杂质必须校正,否则定量结果系统性偏低或偏高。EP/USP 已给出校正因子的按药典执行。Impurities with markedly different UV response need correction, otherwise results are systematically biased. Where EP/USP publish a correction factor, follow the monograph.

强制降解要做全Run the full forced-degradation panel

建议覆盖酸、碱、氧化(H₂O₂)、光照(ICH Q1B)、高温高湿;主峰纯度用二极管阵列或质谱确认。Cover acid, base, peroxide oxidation, photostability (ICH Q1B) and heat/humidity; confirm peak purity by DAD or MS.

定义报告阈值Set reporting and identification thresholds

按 ICH Q3A/Q3B 设定报告阈值、鉴定阈值与界定阈值,避免为无意义的峰投入过多工作量。Apply ICH Q3A/Q3B reporting, identification and qualification thresholds so effort is not spent on insignificant peaks.

标准品储存有讲究Store standards properly

杂质对照品多建议 −20 ℃ 避光、干燥、密封保存;溶液现配现用,并记录开瓶与配制日期。Most impurity standards should be stored at −20 °C, protected from light and moisture; prepare solutions fresh and record opening and preparation dates.

用结构式先做初判Start from the structure

先比对杂质与主成分的结构差异,可预判其保留行为、紫外响应与可能的降解路径,能显著减少试错。Comparing the impurity structure with the parent drug predicts retention behaviour, UV response and probable degradation routes, cutting trial and error.

以上为通行的杂质研究实践提示,不针对具体品种给出结论。实际限度、校正因子与色谱条件请以 EP/USP 各论及你们的验证数据为准。需要某个杂质的结构确证资料、COA 或定制合成,可直接联系我们。The above are general impurity-profiling notes and are not conclusions about this specific drug substance. Actual limits, correction factors and chromatographic conditions follow the EP/USP monograph and your own validation data. Contact us for structural confirmation data, COAs or custom synthesis.
索取杂质谱报价 / COARequest a quote / COA← 查看其它品种← Other drug substances